On July 28, Boston Scientific rose 3.03% in regular trading, trading at $47.05/share, with turnover of $281 million.

On the news front, the company disclosed a global restructuring program in a regulatory filing, expecting to incur pre-tax charges of $700 million to $800 million. The program encompasses supply chain optimization and headcount reduction, set to begin this year and substantially complete by the end of 2029. Notably, the restructuring is projected to deliver approximately $500 million in annual pre-tax cost savings, with the company planning to reinvest a substantial portion of those savings in growth initiatives.

Additionally, Boston Scientific is scheduled to release quarterly earnings on July 29 before market open. Consensus estimates call for revenue of approximately $5.364 billion, representing 9.63% year-over-year growth, and adjusted EPS of $0.83, up 14.13% year-over-year. UBS lowered its price target from $95 to $74 on the same day but maintained a buy rating, with the target still significantly above the current stock price. The broader Health Care Equipment sector also showed strength, with Medtronic up 4.76%, Becton Dickinson up 4.74%, Abbott Laboratories up 3.98%, and Stryker up 3.53%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)